Results 131 to 140 of about 3,619 (166)
Some of the next articles are maybe not open access.
Monkeypox (Mpox) Vaccine Hesitancy Among Mpox Cases: A Qualitative Study
Health Promotion Practice, 2023Human mpox has been an increasing concern in the United States and California since late 2022. While the Jynneos vaccine offers a degree of cross-protection against the disease, vaccine hesitancy is common among those recommended for vaccination. The purpose of this study was to assess vaccine knowledge, facilitators, and barriers to vaccine uptake ...
Harit Agroia +4 more
openaire +3 more sources
An early pop-up mpox vaccine clinic
Journal of the American Association of Nurse Practitioners, 2023ABSTRACT Mpox, formerly known as monkeypox, emerged as a viral zoonotic disease in 2022. The World Health Organization (WHO) declared a global pandemic in July 2022. Through the U.S. Food and Drug Administration's emergency use authorization, JYNNEOS became the dominant vaccine for prevention of mpox. California leads the nation in the number
Rodney W. Hicks, Christopher Blackwell
openaire +2 more sources
Predicting vaccine effectiveness in Mpox
2023Abstract The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent Mpox during the 2022 global outbreak. This vaccine was initially approved for Mpox based on its reported immunogenicity and effectiveness in animal models, rather than evidence of clinical efficacy.
Matthew T. Berry +8 more
openaire +1 more source
Patent Profile for the Approved and in Clinical Trials Mpox Vaccines
Pharmaceutical Patent Analyst, 2023Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines.
Irene von der Weid +3 more
openaire +2 more sources
Vaccines for Mpox — An Unmet Global Need
NEJM EvidenceIn 1970, the first case of mpox (formerly known as monkeypox) was documented in an infant in Equateur Province, Democratic Republic of Congo (DRC).1 Infections with clade I monkeypox virus (MPXV) are endemic in the rainforest regions of central Africa and result from both zoonotic and human-to-human transmission.
Lori E, Dodd +2 more
openaire +2 more sources
Mpox Update: Clinical Presentation, Vaccination Guidance, and Management
Cutis, 2023Following the eradication of smallpox, intermittent small outbreaks of mpox (monkeypox) have occurred with increasing frequency, primarily in endemic regions of Africa. With the rapid spread of mpox around the globe in 2022, we are approaching a second zoonotic pandemic of the 21st century.
Ahuva, Cices +6 more
openaire +2 more sources
Mpox after vaccination: a case series
Sexually Transmitted Infections, 2023Inês Aparício Martins +3 more
openaire +2 more sources
Disaster Medicine and Public Health Preparedness
Abstract Objective 2022 - 2023 mpox outbreak necessitated rapid distribution of JYNNEOS vaccines from US Strategic National Stockpile to state and local public health agencies. New Hampshire’s centralized public health structure required partnering with healthcare facilities to reach at-risk persons.
HeeEun Kang +5 more
openaire +2 more sources
Abstract Objective 2022 - 2023 mpox outbreak necessitated rapid distribution of JYNNEOS vaccines from US Strategic National Stockpile to state and local public health agencies. New Hampshire’s centralized public health structure required partnering with healthcare facilities to reach at-risk persons.
HeeEun Kang +5 more
openaire +2 more sources
Vaccine Effectiveness against Mpox in the United States
New England Journal of Medicine, 2023Nicholas P, Deputy +2 more
openaire +3 more sources